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STARD 2015: an updated list of essential items for
reporting diagnostic accuracy studies
OPEN ACCESS
Incomplete reporting has been identified as a major source of avoidable waste in biomedical research.
Essential information is often not provided in study reports, impeding the identification, critical
appraisal, and replication of studies. To improve the quality of reporting of diagnostic accuracy
studies, the Standards for Reporting Diagnostic Accuracy (STARD) statement was developed. Here
we present STARD 2015, an updated list of 30 essential items that should be included in every
report of a diagnostic accuracy study. This update incorporates recent evidence about sources of
bias and variability in diagnostic accuracy and is intended to facilitate the use of STARD. As such,
STARD 2015 may help to improve completeness and transparency in reporting of diagnostic accuracy
studies.
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As researchers, we talk and write about our studies, not just
because we are happy—or disappointed—with the findings, but
also to allow others to appreciate the validity of our methods,
to enable our colleagues to replicate what we did, and to disclose
our findings to clinicians, other health care professionals, and
decision makers, all of whom rely on the results of strong
research to guide their actions.
Unfortunately, deficiencies in the reporting of research have
been highlighted in several areas of clinical medicine.1 Essential
elements of study methods are often poorly described and
sometimes completely omitted, making both critical appraisal
and replication difficult, if not impossible. Sometimes study
results are selectively reported, and other times researchers
cannot resist unwarranted optimism in interpretation of their
findings.2-4 These practices limit the value of the research and
any downstream products or activities, such as systematic
reviews and clinical practice guidelines.
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Reports of studies of medical tests are no exception. A growing
number of evaluations have identified deficiencies in the
reporting of test accuracy studies.5 These are studies in which
a test is evaluated against a clinical reference standard, or gold
standard; the results are typically reported as estimates of the
test’s sensitivity and specificity, which express how good the
test is in correctly identifying patients as having the target
condition. Other accuracy statistics can be used as well, such
as the area under the receiver operating characteristics (ROC)
curve or positive and negative predictive values.
Despite their apparent simplicity, such studies are at risk of
bias.6 7 If not all patients undergoing testing are included in the
final analysis, for example, or if only healthy controls are
included, the estimates of test accuracy may not reflect the
performance of the test in clinical applications. Yet such crucial
information is often missing from study reports.
It is now well established that sensitivity and specificity are not
fixed test properties. The relative number of false positive and
false negative test results varies across settings, depending on
how patients present and which tests they have already
undergone. Unfortunately, many authors also fail to completely
report the clinical context and when, where, and how they
identified and recruited eligible study participants.8 In addition,
sensitivity and specificity estimates can differ because of
variable definitions of the reference standard against which the
test is being compared. Thus this information should be available
in the study report.
The 2003 STARD statement
To assist in the completeness and transparency of reporting
diagnostic accuracy studies, a group of researchers, editors, and
other stakeholders developed a minimum list of essential items
that should be included in every study report. The guiding
principle for developing the list was to select items that, if
described, would help readers to judge the potential for bias in
the study and appraise the applicability of the study findings
and the validity of the authors’ conclusions and
recommendations.
The resulting Standards for Reporting Diagnostic Accuracy
(STARD) statement appeared in 2003 in two dozen journals.9
It was accompanied by editorials and commentaries in several
other publications and endorsed by many more.
Since the publication of STARD, several evaluations have
pointed to small but statistically significant improvements in
reporting accuracy studies (mean gain 1.4 items (95%
confidence interval 0.7 to 2.2)).5 10 Gradually, more of the
essential items are being reported, but the situation remains far
from optimal.
Methods for developing STARD 2015
The STARD steering committee periodically reviews the
literature for potentially relevant studies to inform a possible
update. In 2013, the steering committee decided that the time
was right to update the checklist.
Updating had two major goals: first, to incorporate recent
evidence about sources of bias, applicability concerns, and
factors facilitating generous interpretation in test accuracy
research, and, second, to make the list easier to use. In making
modifications, we also considered harmonization with other
reporting guidelines, such as Consolidated Standards of
Reporting Trials (CONSORT) 2010.11
A complete description of the updating process and the
justification for the changes are available on the Enhancing the
Quality and Transparency of Health Research (EQUATOR)
website at www.equator-network.org/reporting-guidelines/stard.
In short, we invited the 2003 STARD group members to
participate in the updating process, nominate new members,
and comment on the general scope of the update. Suggested
new members were contacted. As a result, the STARD group
has now grown to 85 members that include researchers, editors,
journalists, evidence synthesis professionals, funders, and other
stakeholders.
STARD group members were then asked to suggest, and later
to endorse, proposed changes in a two round, web based survey.
This served to prepare a draft list of essential items, which was
discussed in the steering committee in a two day meeting in
Amsterdam in September 2014. The list was then piloted in
different groups: starting and advanced researchers, peer
reviewers, and editors.
The general structure of STARD 2015 is similar to that of
STARD 2003. A one page document presents 30 items, grouped
under sections that follow the introduction, methods, results,
and discussion (IMRAD) structure of a scientific article (see
table 1⇓). Several of the STARD 2015 items are identical to the
ones in the 2003 version. Others have been reworded, combined,
or (if complex) split. A few have been added (see table 2⇓ for
a summary of new items and table 3⇓ for key terms). A diagram
to describe the flow of participants through the study is now
expected in all reports (figure⇓).
Scope
STARD 2015 replaces the original version published in 2003;
those who would like to refer to STARD are invited to cite this
article. The list of essential items can be seen as a minimum set,
and an informative study report will typically present more
information. Yet we hope to find all applicable items in a well
prepared report of a diagnostic accuracy study.
Authors are invited to use STARD when preparing their study
reports. Reviewers can use the list to verify that all essential
information is available in a submitted manuscript and suggest
changes if key items are missing.
We trust that journals that endorsed STARD in 2003 or later
will recommend the use of this updated version and encourage
compliance in submitted manuscripts. We hope that even more
journals, and journal organizations, will promote the use of this
and comparable reporting guidelines. Funders and research
institutions may promote or mandate adherence to STARD as
a way to maximize the value of research and downstream
products or activities.
STARD may also be beneficial for reporting other studies that
evaluate the performance of tests. This includes prognostic
studies, which can classify patients on the basis of whether a
future event happens; monitoring studies, in which tests are
supposed to detect or predict an adverse event or lack of
response; studies evaluating treatment selection markers; and
more. We and others have found most of the STARD items
useful when reporting and examining such studies, although
STARD primarily targets diagnostic accuracy studies.
Diagnostic accuracy is not the only expression of test
performance, nor is it always themost meaningful.12 Incremental
accuracy from combining tests, relative to a single test, can be
more informative, for example.13 For continuous tests,
dichotomization into test positives and negatives may not always
be indicated. In such cases, the desirable computational and
graphical methods for expressing test performance are different,
although many of the methodological precautions would be the
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same, and STARD can help in reporting the study in an
informative way. Other reporting guidelines target more specific
forms of tests, such as Transparent Reporting of aMultivariable
Prediction Model for Individual Prognosis or Diagnosis
(TRIPOD) for multivariable prediction models.14
Although STARD focuses on full study reports of test accuracy
studies, the items can also be helpful when writing conference
abstracts, including information in trial registries, and
developing protocols for such studies. Additional initiatives are
underway to provide more specific guidance for each of these
applications.
STARD extensions and applications
The STARD statement was designed to apply to all types of
medical tests. The STARDgroup believed that a single checklist,
for all diagnostic accuracy studies, would be more widely
disseminated and more easily accepted by authors, peer
reviewers, and journal editors than separate lists for different
types of tests such as imaging, biochemistry, or histopathology.
Having a general list may necessitate additional instructions for
informative reporting, with more information for specific types
of tests, specific applications, or specific forms of analysis. Such
guidance could describe the preferred methods for studying and
reporting measurement uncertainty, for example, without
changing any of the other STARD items. The STARD group
welcomes the development of such STARD extensions and
invites interested groups to contact the STARD executive
committee before developing them.
Other groups may want to develop additional guidance to
facilitate the use of STARD for specific applications. An
example of such a STARD application was prepared for history
taking and physical examination.15 Another type of application
is the use of STARD for specific target conditions such as
dementia.16
Availability
The new STARD 2015 list and all related documents can be
found on the STARD pages of the EQUATOR website.
EQUATOR is an international initiative that seeks to improve
the value of published health research literature by promoting
transparent and accurate reporting and wider use of robust
reporting guidelines.17 18 The STARD group believes that
working more closely with EQUATOR and other reporting
guideline developers will help us to better reach shared
objectives. We have updated the 2003 explanation and
elaboration document, which can also be found at the
EQUATOR website. This document explains the rationale for
each item and gives examples.
The STARD list is released under a Creative Commons license.
This allows everyone to use and distribute the work if they
acknowledge the source. The STARD statement was originally
reported in English, but several groups have worked on
translations in other languages. We welcome such translations,
which are preferably developed by groups of researchers, by
use of a cyclical development process, with back-translation to
the original language and user testing.19 We have also applied
for a trademark for STARD to ensure that the steering committee
has the exclusive right to use the word “STARD” to identify
goods or services.
Increasing value, reducing waste
The STARD steering committee is aware that building a list of
essential items is not sufficient to achieve substantial
improvements in reporting completeness, as the modest
improvement after introduction of the 2003 list has shown. We
see this list not as the final product, but as the starting point for
building more specific instruments to stimulate complete and
transparent reporting, such as a checklist and a writing aid for
authors, tools for reviewers and editors, instruction videos, and
teaching materials, all based on this STARD list of essential
items.
Incomplete reporting has been identified as one of the sources
of avoidable waste in biomedical research.1 Since STARD was
initiated, several other initiatives have been undertaken to
enhance the reproducibility of research and promote greater
transparency.20 Multiple factors are at stake, but incomplete
reporting is one of them. We hope that this update of STARD,
together with additional implementation initiatives, will help
authors, editors, reviewers, readers, and decision makers to
collect, appraise, and apply the evidence needed to strengthen
decisions and recommendations about medical tests. In the end,
we are all to benefit from more informative and transparent
reporting: as researchers, as healthcare professionals, as payers,
and as patients.
This article is being simultaneously published in October 2015 by The
BMJ, Radiology, and Clinical Chemistry. This article is published under
the Creative Commons CC BY-NC license http://creativecommons.org/
licenses/by-nc/4.0.
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Tables
Table 1| The STARD 2015 list*
ItemNoSection and topic
Title or abstract
Identification as a study of diagnostic accuracy using at least one measure of accuracy (such as sensitivity,
specificity, predictive values, or AUC)
1
Abstract
Structured summary of study design, methods, results, and conclusions (for specific guidance, see STARD
for Abstracts)
2
Introduction
Scientific and clinical background, including the intended use and clinical role of the index test3
Study objectives and hypotheses4
Methods
Whether data collection was planned before the index test and reference standard were performed (prospective
study) or after (retrospective study)
5Study design
Eligibility criteria6Participants
On what basis potentially eligible participants were identified (such as symptoms, results from previous tests,
inclusion in registry)
7
Where and when potentially eligible participants were identified (setting, location, and dates)8
Whether participants formed a consecutive, random, or convenience series9
Index test, in sufficient detail to allow replication10aTest methods
Reference standard, in sufficient detail to allow replication10b
Rationale for choosing the reference standard (if alternatives exist)11
Definition of and rationale for test positivity cut-offs or result categories of the index test, distinguishing
pre-specified from exploratory
12a
Definition of and rationale for test positivity cut-offs or result categories of the reference standard, distinguishing
pre-specified from exploratory
12b
Whether clinical information and reference standard results were available to the performers or readers of
the index test
13a
Whether clinical information and index test results were available to the assessors of the reference standard13b
Methods for estimating or comparing measures of diagnostic accuracy14Analysis
How indeterminate index test or reference standard results were handled15
How missing data on the index test and reference standard were handled16
Any analyses of variability in diagnostic accuracy, distinguishing pre-specified from exploratory17
Intended sample size and how it was determined18
Results
Flow of participants, using a diagram19Participants
Baseline demographic and clinical characteristics of participants20
Distribution of severity of disease in those with the target condition21a
Distribution of alternative diagnoses in those without the target condition21b
Time interval and any clinical interventions between index test and reference standard22
Cross tabulation of the index test results (or their distribution) by the results of the reference standard23Test results
Estimates of diagnostic accuracy and their precision (such as 95% confidence intervals)24
Any adverse events from performing the index test or the reference standard25
Discussion
Study limitations, including sources of potential bias, statistical uncertainty, and generalisability26
Implications for practice, including the intended use and clinical role of the index test27
Other information
Registration number and name of registry28
Where the full study protocol can be accessed29
Sources of funding and other support; role of funders30
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Table 1 (continued)
ItemNoSection and topic
*At the start of each item row, authors should specify the page number of the manuscript where the item can be found.
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Table 2| Summary of new items in STARD 2015
RationaleItemNo
Abstracts are increasingly used to identify key elements of study design and results.Structured abstract2
Describing the targeted application of the test helps readers to interpret the implications of reported accuracy
estimates.
Intended use and clinical role of the test3
Not having a specific study hypothesis may invite generous interpretation of the study results and “spin” in the
conclusions.
Study hypotheses4
Readers want to appreciate the anticipated precision and power of the study and whether authors were successful
in recruiting the targeted number of participants.
Sample size18
To prevent jumping to unwarranted conclusions, authors are invited to discuss study limitations and draw conclusions
keeping in mind the targeted application of the evaluated tests (see item 3).
Structured discussion26-27
Prospective test accuracy studies are trials, and, as such, they can be registered in clinical trial registries, such
as ClinicalTrials.gov, before their initiation, facilitating identification of their existence and preventing selective
reporting.
Registration28
The full study protocol, with more information about the predefined study methods, may be available elsewhere,
to allow more fine grained critical appraisal.
Protocol29
Awareness of the potentially compromising effects of conflicts of interest between researchers’ obligations to abide
by scientific and ethical principles and other goals, such as financial ones; test accuracy studies are no exception.
Sources of funding30
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Table 3| Key STARD terminology
ExplanationTerm
Any method for collecting additional information about the current or future health status of a patientMedical test
The test under evaluationIndex test
The disease or condition that the index test is expected to detectTarget condition
The best available method for establishing the presence or absence of the target condition; a gold standard would be an error-free
reference standard
Clinical reference standard
Proportion of those with the target condition who test positive with the index testSensitivity
Proportion of those without the target condition who test negative with the index testSpecificity
Whether the index test is used for diagnosis, screening, staging, monitoring, surveillance, prediction, prognosis, or other reasonsIntended use of the test
The position of the index test relative to other tests for the same condition (for example, triage, replacement, add-on, new test)Role of the test
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Figure
Prototypical STARD diagram to report flow of participants through the study.
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